What Is a Qualified Person (QP) in the Pharmaceutical Industry?

Qualified person signing a closed binder at a desk beside a cleanroom window with capped vials, qualified person in the pharmaceutical industry

In EU law, a qualified person (QP) in the pharmaceutical industry is at the disposal of the holder of a manufacturing authorisation and certifies each batch before release. This post explains where the QP is placed in EU law, the QP’s duties and qualifications, and what the requirement means for a company that supplies the EU without an EU site.

Key Takeaways

  • The holder of a manufacturing authorisation (MIA) must have “permanently and continuously” at its disposal at least one QP (Article 48(1) of Directive 2001/83/EC).
  • The QP certifies in a register that each batch meets Article 51. The marketing authorisation holder (MAH) keeps the ultimate responsibility for the product (EU GMP Annex 16).
  • Article 49 requires a qualifying university course, normally of at least four years, and at least two years’ practical experience in an authorised manufacturer; the experience period is shorter after a course of five or six years.
  • In Ireland, to add a QP the employer applies for a variation to its MIA; if approved, the QP’s name and qualifications are included on the MIA (HPRA guide AUT-G0080, sections 8.4 and 8.5).
  • A company with no EU site relies on a QP of the manufacturer or importer described in its MA (Annex 16, section 1.1).

What is a qualified person in the pharmaceutical industry?

A qualified person is the person who certifies that each batch of a medicinal product meets the legal requirements before it is released. The QP meaning in the pharmaceutical industry comes from Directive 2001/83/EC. Article 48(1) requires the holder of the manufacturing authorisation to have at its disposal at least one qualified person, “in accordance with the conditions laid down in Article 49, responsible in particular for carrying out the duties specified in Article 51.”

Article 51(3) sets out the certification duty. The QP “must certify in a register or equivalent document provided for that purpose, that each production batch satisfies the provisions of this Article”. A pharmaceutical qualified person must therefore meet the qualifications in Article 49, carry out the duties in Article 51 and be at the disposal of the holder of a manufacturing authorisation (Article 48). Our guide to what QP release involves covers the certification process itself.

Where the law puts the QP: the MIA holder

Article 41(c) of the Directive makes it a condition of the authorisation: the applicant shall “have at his disposal the services of at least one qualified person within the meaning of Article 48”. Article 48(1) then makes it a continuing duty of the holder.

The holder can also be the QP. Article 48(2) says: “If he personally fulfils the conditions laid down in Article 49, the holder of the authorization may himself assume the responsibility referred to in paragraph 1.”

EU GMP makes the QP one of the site’s key personnel. Section 2.5 of Chapter 2 of the EU GMP guide says: “Senior Management should appoint Key Management Personnel including the head of Production, the head of Quality Control, and if at least one of these persons is not responsible for the duties described in Article 51 of Directive 2001/83/EC, an adequate number, but at least one, Qualified Person(s) designated for the purpose.”

Investigational medicinal products

The same model applies to clinical trial supplies. Under Article 61(2)(b) of Regulation (EU) No 536/2014, the applicant for an authorisation to manufacture or import investigational medicinal products (IMPs) “shall have permanently and continuously at its disposal the services of at least one qualified person who fulfils the conditions of qualification set out in Article 49(2) and (3) of Directive 2001/83/EC”. Article 62(1) requires the QP to ensure, and certify, that each IMP batch made in or imported into the Union meets Article 63.

The QP on an Irish MIA

The HPRA guide to attainment of Qualified Person status in Ireland (AUT-G0080, version 6, 18 August 2026) gives the Irish definition in section 2. A QP is “a person with the qualifications and experience specified in Schedule 5 and named in the manufacturer’s authorisation as being responsible at the manufacturer’s premises for the functions set out in Regulation 13(3) of Medicinal Products (Control of Manufacture) Regulations 2007 (S.I. No. 539 of 2007), as amended”.

The guide describes how a QP is added. Section 8.5: “Your employer should submit an application for variation to its MIA to request that you be added as a QP.” Section 8.4: “As part of the assessment of the application your experience and training are reviewed to determine if you can act in the capacity of a QP. If approved, your name and qualifications are included on the MIA.” Our post on applying for an MIA in Ireland covers the authorisation itself.

What the QP is responsible for, and what stays with the MAH

The QP’s duties are set out in Article 51(1). They apply “without prejudice to his relationship with the holder of the manufacturing authorization”. The QP is responsible for securing that:

  • for products made in the Member State, each batch was manufactured and checked “in compliance with the laws in force in that Member State and in accordance with the requirements of the marketing authorization” (point (a));
  • for products coming from third countries, “irrespective of whether the product has been manufactured in the Community”, each production batch “has undergone in a Member State a full qualitative analysis, a quantitative analysis of at least all the active substances and all the other tests or checks necessary to ensure the quality of medicinal products in accordance with the requirements of the marketing authorisation” (point (b)). Under Article 51(2), where the Community has made appropriate arrangements with the exporting country to ensure that the manufacturer applies GMP standards at least equivalent to the Community’s, and that the controls under point (b) have been carried out in the exporting country, “the qualified person may be relieved of responsibility for carrying out those controls.”

For products placed on the market in the Union, the QP must also “ensure that the safety features referred to in point (o) of Article 54 have been affixed on the packaging.” Under Article 51(3), the certification is recorded in a register, which remains at the disposal of the competent authority for the period set by the Member State and “in any event for at least five years”.

EU GMP Annex 16 distinguishes the responsibilities of the QP from those of the MAH. Its general principles say that “the ultimate responsibility for the performance of a medicinal product over its lifetime, its safety, quality and efficacy, lies with the marketing authorisation holder (MAH).” The QP is responsible for ensuring that “each individual batch” was manufactured and checked in line with the law of the Member State where certification takes place, the requirements of the MA and GMP.

Section 1.6 lists what the QP “must personally ensure” before certifying a batch for release to market or for export:

  1. Certification is permitted under the terms of the MIA.
  2. Any additional duties and requirements of national legislation are complied with.
  3. Certification is recorded in a register or equivalent document.

What qualifications does a QP need, and how do you become one?

Article 49 of the Directive sets the qualified person requirements in the EU. To become a qualified person, a candidate needs a qualifying university course, or a recognised equivalent, and practical experience.

Education: Article 49(2)

The QP needs a formal qualification from a university course, or a course the Member State recognises as equivalent, “extending over a period of at least four years of theoretical and practical study” in pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry and technology, or biology.

A course of three and a half years can also qualify, where it is “followed by a period of theoretical and practical training of a minimum duration of one year and including a training period of at least six months in a pharmacy open to the public, corroborated by an examination at university level.”

The course must also cover a set list of basic subjects, including experimental physics, analytical chemistry, pharmacology, toxicology and pharmacognosy. If a diploma does not meet these criteria, the competent authority must ensure that the person provides “evidence of adequate knowledge of the subjects involved.”

Experience: Article 49(3)

The QP also needs “practical experience over at least two years, in one or more undertakings which are authorized to manufacture medicinal products, in the activities of qualitative analysis of medicinal products, of quantitative analysis of active substances and of the testing and checking necessary to ensure the quality of medicinal products.”

The period is reduced “by one year where a university course lasts for at least five years and by a year and a half where the course lasts for at least six years.”

In Ireland, section 8.6 of the HPRA guide says that a course recognised in another EEA state as meeting the Directive “is recognised in Ireland as being equivalent”.

How QPs are held to their duties

Article 52 leaves enforcement to the Member States: “Member States shall ensure that the duties of qualified persons referred to in Article 48 are fulfilled, either by means of appropriate administrative measures or by making such persons subject to a professional code of conduct.” Member States may also provide for a QP’s temporary suspension once administrative or disciplinary procedures begin for failure to fulfil those obligations.

QP or RP?

The QP is required under a manufacturing or import authorisation, and the Responsible Person (RP) is required under a wholesale distribution authorisation. Article 79(b) of the Directive says that applicants for a wholesale distribution authorisation “must have staff, and in particular, a qualified person designated as responsible, meeting the conditions provided for by the legislation of the Member State concerned.”

Article 79(b) leaves the RP’s qualifications to national law. Section 2.2 of the EU Guidelines on Good Distribution Practice (2013/C 343/01) says the wholesale distributor “must designate a person as responsible person” and that “A degree in pharmacy is desirable.” The RP’s responsibilities include “ensuring that a quality management system is implemented and maintained” and “coordinating and promptly performing any recall operations for medicinal products”.

The QP in the UK (Great Britain)

This section covers Great Britain, under UK law. The Human Medicines Regulations 2012 set the rules there. Regulation 41(2) says: “The licence holder must ensure that there is at the disposal of the holder at all times at least one qualified person”. Where the QP changes, regulation 41(6) says the licence holder “must give the licensing authority advance notification”.

In Great Britain, the qualified person requirements are in Schedule 7: a formal qualification in subjects including pharmacy, medicine, chemistry and biology, from a course of “at least four years”, and “at least two years’ practical experience in an undertaking authorised to manufacture medicinal products”. Under regulation 41(4) and (5), a QP may be treated as meeting Schedule 7 if a member of, and regarded as meeting the requirements by, one of the listed bodies: the Society of Biology, the Royal Pharmaceutical Society, the Pharmaceutical Society of Northern Ireland or the Royal Society of Chemistry, or another body the licensing authority specifies.

What this means if your company has no EU site

If a company has no EU manufacturing or import site, and therefore no MIA, it does not have its own QP under Article 48. Annex 16 section 1.1 sets the rule for every batch: “Each batch of finished product must be certified by a QP within the EU before being released for sale or supply in the EU or for export. Certification can only be performed by a QP of the manufacturer and/or importer which are described in the MA.”

In that case, your batches must be certified, against your MA, by a QP of the manufacturer or importer described in that MA. Your company, as MAH, keeps the ultimate responsibility for the product. Our post on using another company’s MIA explains how importing under another company’s authorisation works and who is responsible for what.

How Inglasia can help

Inglasia’s QPs review manufacturing records, technical documentation and test results and certify batches under Annex 16, as described on our QP batch release services page. To discuss QP certification for your product, contact us.

Categories :
Share it :

Leave a Reply

Your email address will not be published. Required fields are marked *